Sutter Memory Clinic Study Shows IVIG Could Be Key to Alzheimer’s Cure

SACRAMENTO, Calif., Oct. 12, 2015 /PRNewswire/ — In a Sutter Institute of Medical Research study published this month in the Journal of Neurology, Neurosurgery, and Psychiatry, the blood product intravenous immunoglobulin, or IVIG, was found to reduce brain atrophy and cognitive decline in patients in the early, pre-dementia phase of Alzheimer’s disease.IVIG, extracted from the plasma of more than 1,000 blood donors, contains antibodies to amyloid, an abnormal brain protein found in patients with Alzheimer’s disease. Sutter Institute of Medical Research, in partnership with Sutter Neuroscience Institute and Sutter Neuroradiology, designed the study to investigate if a course of IVIG could have practical, disease-modifying effects on Alzheimer’s disease when administered during the pre-dementia phase. The study showed promising results during the first year after treatment in the form of reduced brain…


Link to Full Article: Sutter Memory Clinic Study Shows IVIG Could Be Key to Alzheimer’s Cure